Obesity therapy Saxenda lands in 10 general hospitals including Seoul National University Hospital
Novo Nordisk Korea(CEO Rana Azfar Zafar) announced on the 21st that ‘Saxenda® (generic name: liraglutide 3.0mg),’ the world’s first and only GLP-1(Glucagon-Like Peptide 1) analogue for the treatment of obesity, will be extensively landing into 10 general hospitals including Seoul National Univers...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.